Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Thomas Gad Insider Profile
4 Followers
Thomas Gad, CBO, Director at Y-Mabs Therapeutics, holds 381.38K shares in Y-Mabs Therapeutics (Ticker: YMAB). Most recently, Thomas Gad Sold $70,000 shares of Y-Mabs Therapeutics on Jun 11, 2024 for an estimated value of 841.05K.
Profitable Transactions
15 out of 20 Profitable Transactions
Average Return
+20.70%
Average return per transaction
Time Frame
Compare to
Insider Roles
CBO, Director
Roles that Thomas Gad holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Nov 26, 2021 - Nov 26, 2022
Return:+75.50%
The most profitable trade made by Thomas Gad
Thomas Gad's Trading History
List of latest transactions for each holding click on a transaction to see Thomas Gad's performance on stock
You May Also Like
Thomas Gad insider profile FAQ
What is the percentage of profitable transactions made by Thomas Gad?
The percentage of profitable transactions made by Thomas Gad is 75%.
What is the average return per transaction made by Thomas Gad?
The average return per transaction made by Thomas Gad is 20.70%.
What stocks does Thomas Gad hold?
Thomas Gad holds: YMAB stocks.
What was Thomas Gad’s latest transaction?
Thomas Gad latest transaction was an Informative Sell of $841.05K.
What was Thomas Gad's most profitable transaction?
Thomas Gad’s most profitable transaction was an Informative Sell of YMAB stock on November 26, 2021. The return on the trade was 75.50%.
What is Thomas Gad's role in Y-Mabs Therapeutics?
Thomas Gad's role in Y-Mabs Therapeutics is CBO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.